← Vir Biotechnology, Inc. (VIR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vir Biotechnology, Inc. (VIR)
Biological Products, (No Diagnostic Substances) · market cap $1.9B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
10
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Vir Biotechnology (VIR) is a ~$1.6B market-cap infectious disease and oncology biotech with 408 employees and a multi-asset pipeline centered on hepatitis B/D eradication. The company generated over $1.6B in revenue in 2022 from COVID-19 antibody sotrovimab but has since reverted to a cash-burn phase, carrying $809M in cash against ~18 months of runway. Its highest-priority near-term catalyst is a Phase 3 readout for elebsiran in viral hepatitis expected around December 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-11-15 (est.)Phase 2 · Bulevirtideimp 7/10
- 2026-12-15 (est.)Phase 3 · Elebsiranimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tobevibart | Phase 3 | Viral Hepatitis |
| Elebsiran | Phase 3 | Viral Hepatitis |
| Sotrovimab (Gen1) | Phase 2 | Covid19 |
| VIR-7831 (sotrovimab) | Phase 3 | Covid19 |
| NRTI | Phase 2 | Hepatitis D, Chronic |
| VIR-2218 | Phase 2 | Hepatitis B, Chronic |
| pegylated interferon-alfa 2a | Phase 2 | Chronic Hepatitis B |
| VIR-5818 | Phase 2 | Locally Advanced or Metastatic HER2-Expressing Cancers |
| VIR-3434 | Phase 2 | Hepatitis B, Chronic |
| Bulevirtide | Phase 3 | Viral Hepatitis |
Price & technical context
3-month
+12.5%
6-month
+25.2%
12-month
+97.7%
52-wk range
$5.12–$11.63
vs 50-day MA
+11.8%
vs 200-day MA
+25.4%
Realized vol
63.2%
Max drawdown
-65.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VIR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.